Dr. Sandip B. Bharate

g) Citation (summary) on the outstanding research work on which the award is claimed in about 250 words signed by the nominator.

Dr. Bharate has significantly contributed to the new drug discovery through his research efforts in natural products chemistry and medicinal chemistry. His specific research areas include the discovery of small-molecule kinase inhibitors for cancer and multi-targeted drug ligands for Alzheimer's disease. The small molecule CDK9 inhibitor, IIIM-290, discovered by his group has reached the clinical trial. The DCGI permission has been received for conducting a phase I/II clinical trial in metastatic pancreatic cancer patients. Recently his group has discovered another follow-on CDK9/T1 inhibitor from rohitukine scaffold (rohitukine-N-oxide derivative) with an efficacy in pancreatic cancer. His group has also discovered isoform-selective PI3K-alpha inhibitor for the treatment of breast cancer, which is now under IND enabling studies for triple-negative breast cancer (TNBC). His group is also working on discovering multitargeted lead compounds for Alzheimer's disease. Recently, he has discovered an orally bioavailable, blood-brain barrier permeable small molecule, SB-1448 that shows multi-targeted effect against cholinesterases, beta-secretase, amyloid-beta aggregation and shows in vivo anti-dementia activity in mice model.

(D. Srinivasa Reddy)
Director, IICT

Nominator